Sameridine

Sameridine (NIH-10908) is a weak partial agonist of the μ-opioid (μ-opioid) receptor. Sameridine shows local anesthetic and analgesic properties when injected intrathecally. Sameridine has minimal respiratory depression at low doses, but can suppress ventilatory response at high doses. Sameridine can be used for the study of analgesic effect[1][2].

Product Specifications

CAS Number

[143257-97-0]

Product Name Alternative

NIH 10908 (free base)

UNSPSC

12352005

Hazard Statement

H312-H319

Target

Opioid Receptor

Related Pathways

GPCR/G Protein; Neuronal Signaling

Field of Research

Neurological Disease

Smiles

O=C(C1(CCN(CC1)CCCCCC)C2=CC=CC=C2)N(CC)C

Molecular Formula

C21H34N2O

Molecular Weight

330.51

Precautions

P264-P280-P302+P352-P305+P351+P338-P363-P501

References & Citations

[1]Mulroy MF, et al. Sameridine is safe and effective for spinal anesthesia: a comparative dose-ranging study with lidocaine for inguinal hernia repair. Anesth Analg. 1999 Apr;88 (4) :815-21.|[2]Osterlund A, et al. The effects on resting ventilation of intravenous infusions of morphine or sameridine, a novel molecule with both local anesthetic and opioid properties. Anesth Analg. 1999 Jan;88 (1) :160-5.|[3]Karlsten R, et al. Sameridine--intrathecal injection in the rat. Morphometric and morphologic analysis after chronic administration and effects on spinal cord blood flow. Acta Anaesthesiol Scand. 1999 May;43 (5) :573-9.